Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ASI to Open Pharmaceutical Laboratory in Düsseldorf

Published: Thursday, October 04, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
New laboratory will provide technical support to Ashland’s European pharmaceutical and nutraceutical customers.

Ashland Specialty Ingredients (ASI) has announced plans to open a new pharmaceutical application laboratory in Düsseldorf, Germany, in December 2012.

“With a location central to major pharmaceutical and nutraceutical customers in the region, this new lab will enable us to offer sizable value and convenience to global multinational companies as we bring on board research projects,” said Dr. Edmont Stoyanov, technical director pharmaceutical, Europe, the Middle East and Africa, ASI.

Dr. Stoyanov continued, “In addition, it will ensure our capability to realize novel ideas and developments quickly and sharpen our R&D profile. Ultimately, this will help strengthen our position as a leading innovator and deepen our relationship with originator companies.”

The new laboratory will be outfitted with the equipment covering all the processes required for classical pharmaceutical formulation and research.

Staffed with experienced pharmaceutical experts, Ashland’s Düsseldorf lab will ensure that Ashland’s customers continue to receive the high level of technical support to which they’ve grown accustomed, and open doors to promising new opportunities.

The new laboratory will be part of Ashland’s global pharmaceutical facilities network, which includes numerous laboratories and research centers worldwide, facilitating technical assistance for drug solubilization, including hot-melt extrusion and spray drying.

“Placing Ashland’s experienced pharmaceutical experts in Düsseldorf will provide the highest level of technical support for customers in areas like granulation, coating and tableting, including direct compression, roller compaction and wet granulation,” added Stoyanov.

Stoyanov continued, “We can offer our European customers quick and detailed support on all tableting issues. The lab location in Germany will accelerate and optimize the cooperation with the R&D departments of our European customers.”

Additionally, the lab will extend its services to host hands-on applications training and technical seminars for up to 20 people at a time.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!